Overview

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

Status:
Not yet recruiting

Trial end date:
2027-02-15

Target enrollment:

Participant gender:

Summary

It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.

Phase:

Phase 3

Details

Lead Sponsor:

Peking University Cancer Hospital & Institute

Treatments:

Apatinib